盈康生命(300143) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥132,529,203.59, representing a 32.17% increase compared to ¥100,274,479.92 in the same period last year[8]. - Net profit attributable to shareholders was ¥11,473,021.86, a significant turnaround from a loss of ¥11,712,913.85 in the previous year, marking a 197.95% improvement[8]. - Basic and diluted earnings per share were both ¥0.0179, compared to a loss of ¥0.0215 in the same period last year, representing an increase of 183.26%[8]. - Operating profit for the first quarter was CNY 21,954,926.16, a significant increase of 327.62% year-on-year[29]. - Net profit attributable to shareholders reached ¥11,473,021.86, an increase of 197.95% compared to the same period last year[43]. - Total operating revenue for the current period reached ¥132,529,203.59, an increase from ¥100,274,479.92 in the previous period, representing a growth of approximately 32.1%[78]. - Total operating costs increased to ¥138,944,254.06 from ¥110,781,704.13, reflecting a rise of about 25.4%[79]. - Net profit for the current period was ¥13,995,066.86, recovering from a net loss of ¥12,394,791.25 in the previous period[81]. - Total comprehensive income for the current period was ¥14,126,823.59, recovering from a loss of ¥11,890,511.38 in the previous period[81]. Cash Flow and Financial Position - The net cash flow from operating activities was ¥48,937,552.82, reflecting a 44.12% increase from ¥33,956,613.36 in the previous year[8]. - Cash and cash equivalents decreased by 45.71% to CNY 262,584,708.71 due to cash management activities[22]. - The company reported a cash flow increase of ¥175,481,979.16 in the current period, compared to an increase of ¥17,934,303.18 in the previous period[92]. - The total cash inflow from investment activities is ¥199,449,596.93, while the cash outflow is ¥413,896,740.37, resulting in a net cash flow from investment activities of -¥214,447,143.44[89]. - The net cash flow from financing activities is -¥55,639,770.84, compared to a positive net cash flow of ¥23,619,888.89 in the previous period[90]. - The cash and cash equivalents at the end of the period amount to ¥262,584,708.71, a decrease from ¥149,433,767.47 in the previous period[90]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,794,285,488.96, a 5.41% increase from ¥2,650,750,262.62 at the end of the previous year[8]. - Current liabilities decreased to CNY 187,800,076.29 from CNY 200,583,894.04, a reduction of approximately 6.9%[69]. - Total liabilities rose to CNY 589,510,552.08, compared to CNY 410,102,149.33, indicating an increase of around 43.7%[69]. - Owner's equity decreased to CNY 2,204,774,936.88 from CNY 2,240,648,113.29, a decline of about 1.6%[70]. - Total current assets amounted to ¥1.01 billion, slightly down from ¥1.02 billion, indicating a decrease of about 1.3%[66]. Medical Services and Operations - The medical services segment achieved revenue of ¥131,480,000, a 49% increase year-over-year, with outpatient visits up 131% and inpatient visits up 13%[8]. - The company signed contracts for 4 medical devices during the reporting period, with plans to accelerate revenue conversion through a pre-order funnel mechanism[8]. - The medical services segment is advancing the construction of six platform systems to enhance hospital management capabilities[43]. - The maintenance revenue in the medical device segment increased significantly by 248% year-on-year, enhancing user retention and sustainable income[39]. - The company is actively developing high-end radiation therapy equipment, with new models of integrated gamma knives and linear accelerators undergoing testing[40]. Research and Development - Research and development expenses increased to ¥5,723,473.58 from ¥4,425,626.94, marking a rise of approximately 29.3%[79]. - The company is focused on strengthening its R&D capabilities through collaboration with universities and research institutions to maintain its competitive edge[47]. - The company is actively developing new technologies, including advancements in linear accelerators and integrated gamma knife systems[61]. Shareholder and Market Activities - The total number of shareholders at the end of the reporting period was 9,917, with the largest shareholder holding 39.69% of the shares[14]. - The company has repurchased a total of 2,507,917 shares, accounting for 0.39% of the total share capital, with a total payment of approximately 49.98 million RMB[54]. - The company plans to enhance its international market development and diversify domestic market operations to achieve expected performance[48]. Risks and Challenges - The company is facing industry policy risks that may impact its operations in the medical health sector, particularly regarding large-scale radiation therapy equipment[44]. - The company is facing potential competition in the tumor treatment field, which may include new technologies that could replace existing methods[46].